CStone Pharma places shares at 7% discount to raise HKD1.05B

CStone Pharmaceuticals announced a placement of 118 million shares at a 6.95 percent discount, aiming to raise approximately HKD1.053 billion for research and development.

The company said in a filing that about 90 percent of the proceeds will be used for assets under its “Pipeline 2.0” strategy.

The new shares were priced at HKD8.97 each, a discount to the previous closing price of HKD9.64. The placement represents approximately 7.4 percent of the company's enlarged share capital.

The move will dilute existing shareholders but aims to fund potentially best-in-class cancer therapies, including its ROR1 ADC candidate CS5001 and the multi-specific molecule CS2009.

The majority of the net proceeds are earmarked for further research on key assets. These include CS2009, a tri-specific molecule targeting PD-1, VEGFA, and CTLA-4 currently in Phase II, and CS5001, a potential best-in-class ROR1 antibody-drug conjugate. Funds will also support other assets in preclinical or IND-enabling stages, with the remainder used for general corporate purposes.

The capital raise, while putting short-term pressure on the stock price due to dilution, is critical for advancing CStone's next-generation oncology pipeline. Investors will now watch for key development milestones from the CS2009 and CS5001 programs.

This article is for informational purposes only and does not constitute investment advice.